{"id":"risperidone-haloperidol","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Extrapyramidal symptoms (tremor, rigidity, akathisia)"},{"rate":"0.5-5 per year of exposure","effect":"Tardive dyskinesia"},{"rate":"5-15","effect":"Weight gain"},{"rate":"20-50","effect":"Hyperprolactinemia"},{"rate":"10-20","effect":"Sedation"},{"rate":"5-15","effect":"Orthostatic hypotension"},{"rate":"1-5","effect":"QT prolongation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors, while haloperidol is a typical antipsychotic that primarily blocks D2 receptors. Both reduce dopaminergic and serotonergic neurotransmission in key brain regions involved in psychosis, thereby alleviating hallucinations, delusions, and disorganized thinking.","oneSentence":"Risperidone and haloperidol are antipsychotic medications that block dopamine and serotonin receptors in the brain to reduce psychotic symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:20.166Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar disorder (acute mania and maintenance)"},{"name":"Irritability associated with autism spectrum disorder"},{"name":"Acute agitation"}]},"trialDetails":[{"nctId":"NCT06049953","phase":"","title":"Maternal And Infant Antipsychotic Study","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-09-29","conditions":"Antipsychotics, Pregnancy","enrollment":200},{"nctId":"NCT04002700","phase":"","title":"A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-05-06","conditions":"Stroke","enrollment":1234412},{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT03629951","phase":"","title":"A Study for Schizophrenia Relapse Prediction","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-29","conditions":"Schizophrenia","enrollment":333},{"nctId":"NCT04529226","phase":"PHASE2","title":"Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2020-11-26","conditions":"Psychosis, Intellectual Disability","enrollment":75},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT03019887","phase":"NA","title":"Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction","status":"COMPLETED","sponsor":"Juntendo University","startDate":"2011-04","conditions":"Schizophrenia Relapse","enrollment":139},{"nctId":"NCT03451734","phase":"","title":"Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients","status":"COMPLETED","sponsor":"Central South University","startDate":"2018-01-23","conditions":"Schizophrenia, Metabolic Syndrome","enrollment":2000},{"nctId":"NCT04071639","phase":"PHASE1","title":"Symptomatic Therapy for Patients With Huntington's Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-03-12","conditions":"Huntington Disease","enrollment":60},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":"Schizophrenia","enrollment":174},{"nctId":"NCT03075657","phase":"PHASE4","title":"Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2017-05-01","conditions":"Schizophrenia","enrollment":120},{"nctId":"NCT02600741","phase":"","title":"Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-24","conditions":"Schizophrenia","enrollment":296},{"nctId":"NCT01231074","phase":"PHASE1","title":"Reducing Antipsychotic-Induced Weight Gain in Children With Metformin","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2010-02","conditions":"Obesity, Weight Gain, Psychotropic Induced Weight Gain","enrollment":96},{"nctId":"NCT02307396","phase":"PHASE4","title":"Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-02-01","conditions":"Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders","enrollment":21},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT02191358","phase":"","title":"YouScript IMPACT Registry","status":"COMPLETED","sponsor":"Genelex Corporation","startDate":"2014-10","conditions":"Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation","enrollment":800},{"nctId":"NCT02423096","phase":"","title":"Neuroendocrine and Metabolite Substrates in Schizophrenia","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2013-12","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT02192723","phase":"NA","title":"A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia","status":"COMPLETED","sponsor":"Beijing HuiLongGuan Hospital","startDate":"2012-06","conditions":"Schizophrenia","enrollment":550},{"nctId":"NCT00044655","phase":"PHASE4","title":"Switching Medication to Treat Schizophrenia","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2001-07","conditions":"Schizophrenia","enrollment":219},{"nctId":"NCT02582736","phase":"","title":"Antipsychotics and Risk of Hyperglycemic Emergencies","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-04","conditions":"Psychotic Disorders, Schizophrenia, Schizoaffective Disorder","enrollment":725489},{"nctId":"NCT01157351","phase":"PHASE4","title":"15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2010-05","conditions":"Schizophrenia","enrollment":450},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":"Psychosis Nos/Other","enrollment":104},{"nctId":"NCT01323205","phase":"PHASE2","title":"Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-05","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT01193166","phase":"PHASE4","title":"Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital","status":"WITHDRAWN","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2010-08","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT00253110","phase":"PHASE4","title":"A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder","status":"COMPLETED","sponsor":"Janssen, LP","startDate":"1996-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":396},{"nctId":"NCT00833300","phase":"NA","title":"Haloperidol vs Olanzapine for the Management of ICU Delirium","status":"TERMINATED","sponsor":"Richard Hall","startDate":"2008-06","conditions":"Delirium, Agitation","enrollment":200},{"nctId":"NCT00399776","phase":"","title":"Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy","status":"COMPLETED","sponsor":"Creighton University","startDate":"2006-10","conditions":"Adolescent Depression","enrollment":60},{"nctId":"NCT01259973","phase":"PHASE1","title":"Typical Versus Atypical Antipsychotics; Occupation of Striatal Receptors and the Appearance of Extrapyramidal Symptomatology, in Healthy Volunteers","status":"UNKNOWN","sponsor":"Hospital Clinic of Barcelona","startDate":"2011-02","conditions":"Pharmacogenetics, Healthy","enrollment":24},{"nctId":"NCT00249119","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia","status":"COMPLETED","sponsor":"Janssen, LP","startDate":"","conditions":"Schizophrenia, Psychotic Disorder","enrollment":1579},{"nctId":"NCT00249132","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia","status":"COMPLETED","sponsor":"Janssen, LP","startDate":"","conditions":"Schizophrenia, Psychotic Disorders","enrollment":523},{"nctId":"NCT00253162","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Risperidone Compared With Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder, and the Maintenance of Anti-manic Effectiveness of Risperidone Compared With Haloperidol","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2001-03","conditions":"Bipolar Disorders, Manic Disorder","enrollment":439},{"nctId":"NCT00253149","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Risperidone as add-on Therapy to Mood Stabilizers in the Treatment of Manic Episodes Associated With Bipolar Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"","conditions":"Bipolar Disorders, Manic Disorder","enrollment":158},{"nctId":"NCT00249145","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"1995-04","conditions":"Dementia, Alzheimer Disease, Dementia, Vascular","enrollment":349},{"nctId":"NCT01185418","phase":"","title":"Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer","status":"COMPLETED","sponsor":"Chonbuk National University Hospital","startDate":"2009-03","conditions":"Normal Volunteers","enrollment":80},{"nctId":"NCT01016145","phase":"PHASE4","title":"Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2009-04","conditions":"Schizophrenia or Schizoaffective Disorder","enrollment":126},{"nctId":"NCT00998608","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Risperidone Versus Risperidone Plus Low Dose of Haloperidol in the Treatment of Schizophrenia","status":"TERMINATED","sponsor":"Kaohsiung Kai-Suan Psychiatric Hospital","startDate":"2007-08","conditions":"Schizophrenia","enrollment":88},{"nctId":"NCT00859872","phase":"PHASE4","title":"Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia","status":"COMPLETED","sponsor":"Central South University","startDate":"2008-08","conditions":"Schizophrenia","enrollment":198},{"nctId":"NCT00493233","phase":"NA","title":"Antipsychotic Polypharmacy in Schizophrenia","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2006-11","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT00159081","phase":"PHASE4","title":"One Year Drug Treatment in First-Episode Schizophrenia","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2000-11","conditions":"Schizophrenia","enrollment":159},{"nctId":"NCT00174590","phase":"PHASE3","title":"Treatment of Major Depressive Disorder With Psychotic Features.","status":"TERMINATED","sponsor":"Rush University Medical Center","startDate":"2001-09","conditions":"Major Depression With Psychotic Features","enrollment":30},{"nctId":"NCT00534183","phase":"NA","title":"Metabolic Profile and Anthropometric Changes in Schizophrenia","status":"COMPLETED","sponsor":"Central Institute of Psychiatry, Ranchi, India","startDate":"2006-06","conditions":"Metabolic Syndrome, Diabetes, Obesity","enrollment":2006},{"nctId":"NCT00361166","phase":"PHASE2","title":"Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone","status":"COMPLETED","sponsor":"ACADIA Pharmaceuticals Inc.","startDate":"2005-08","conditions":"Schizophrenia","enrollment":400},{"nctId":"NCT00203775","phase":"NA","title":"Haloperidol vs. Risperidone in the Treatment of Aggression in Psychotic Inmates","status":"TERMINATED","sponsor":"University of Connecticut","startDate":"2002-07","conditions":"Psychosis, Aggression","enrollment":""},{"nctId":"NCT00157378","phase":"PHASE4","title":"Optimization of Acute Treatment in First Episode Schizophrenia","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2000-11","conditions":"Schizophrenia, First-Episode","enrollment":300},{"nctId":"NCT00065273","phase":"PHASE3","title":"Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"1998-07","conditions":"Mental Retardation, Developmental Delay Disorder","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":74,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Risperidone, Haloperidol","genericName":"Risperidone, Haloperidol","companyName":"Ludwig-Maximilians - University of Munich","companyId":"ludwig-maximilians-university-of-munich","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Risperidone and haloperidol are antipsychotic medications that block dopamine and serotonin receptors in the brain to reduce psychotic symptoms. Used for Schizophrenia, Bipolar disorder (acute mania and maintenance), Irritability associated with autism spectrum disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}